ABcann Medicinals Inc (ABCN)

[NetworkNewsWire]

ABCN Targets Global Cannabis Market

As a licensed producer under the Marijuana for Medical Purposes Regulations in Canada, ABcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF) sells cannabis through its ABcann Medicinals, Inc. subsidiary. “We’re now, hopefully, going to be a global presence,” director Aaron Keay said in an interview with CannabisFN (CFN Media). An article discussing this reads: “ABcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF) director Aaron Keay said in an interview with CannabisFN (CFN Media) that besides achieving greater market share in Canada, ABcann Global also sees opportunities for growth and presence in Western Europe, Germany and South America (http://nnw.fm/0SwRs). The company sells in its Canadian domestic market through its subsidiary, ABcann Medicinals, Inc.”

To view the full article, visit http://nnw.fm/Z60nx

About ABcann Global Corporation

ABcann was one of the first companies to obtain a production license under the Marijuana for Medical Purposes Regulations, which it received on March 21, 2014. It obtained a sales license on December 31, 2015. ABcann’s flagship facility, in Napanee, Ontario, contains proprietary plant-growing technology, including environmentally-controlled chambers capable of monitoring and regulating all variables in the growing process. This approach and the systems in place allow ABcann to produce organically grown and pesticide-free, high-yielding plants, which, in turn, can generate high-quality products that are consistent from batch to batch. ABcann is able to control environmental and nutrient demands, tailor-made for a particular strain of cannabis, without the variation that is typical when producing large quantities in less-controlled, larger rooms and greenhouse-type structures. ABcann’s modular approach to systems technology eliminates scale-up risk and allows ABcann to locate anywhere in the world and maintain consistency and quality of product. For more information, visit www.ABcannGlobal.com.